Journal article icon

Journal article

Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial.

Abstract:

OBJECTIVES: To evaluate the efficacy and safety of intravenous ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, active rheumatoid arthritis (RA) patients despite methotrexate treatment. METHODS: In this double-blind, placebo-controlled, phase III study, active RA patients on stable methotrexate were randomly assigned to one course of two infusions of ofatumumab 700 mg (n=130) or placebo (n=130), 2 weeks apart. The primary endpoint was the ACR20 response at week 2...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1136/ard.2011.151522

Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, NDORMS
Role:
Author
Expand authors...
Journal:
Annals of the rheumatic diseases
Volume:
70
Issue:
12
Pages:
2119-2125
Publication date:
2011-12-05
DOI:
EISSN:
1468-2060
ISSN:
0003-4967
URN:
uuid:ba440a1a-4d8c-4198-8db4-01c182c98a37
Source identifiers:
329928
Local pid:
pubs:329928

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP